• Je něco špatně v tomto záznamu ?

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

LA. Asbagh, I. Vazquez, L. Vecchione, E. Budinska, V. De Vriendt, MF. Baietti, M. Steklov, B. Jacobs, N. Hoe, S. Singh, NS. Imjeti, P. Zimmermann, A. Sablina, S. Tejpar,

. 2014 ; 5 (20) : 10070-83.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031799

Inappropriate activation of epidermal growth factor receptor (EGFR) plays a causal role in many cancers including colon cancer. The activation of EGFR by phosphorylation is balanced by receptor kinase and protein tyrosine phosphatase activities. However, the mechanisms of negative EGFR regulation by tyrosine phosphatases remain largely unexplored. Our previous results indicate that protein tyrosine phosphatase receptor type O (PTPRO) is down-regulated in a subset of colorectal cancer (CRC) patients with a poor prognosis. Here we identified PTPRO as a phosphatase that negatively regulates SRC by directly dephosphorylating Y416 phosphorylation site. SRC activation triggered by PTPRO down-regulation induces phosphorylation of both EGFR at Y845 and the c-CBL ubiquitin ligase at Y731. Increased EGFR phosphorylation at Y845 promotes its receptor activity, whereas enhanced phosphorylation of c-CBL triggers its degradation promoting EGFR stability. Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO leads to high resistance of colon cancer to EGFR inhibitors. Our results not only highlight the PTPRO contribution in negative regulation of SRC/EGFR signaling but also suggest that tumors with low PTPRO expression may be therapeutically targetable by anti-SRC therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031799
003      
CZ-PrNML
005      
20151014103731.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.2458 $2 doi
035    __
$a (PubMed)25301722
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Asbagh, Layka Abbasi $u Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium. Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium. Center for Human Genetics, KU Leuven, Leuven, Belgium. $7 gn_A_00009198
245    14
$a The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling / $c LA. Asbagh, I. Vazquez, L. Vecchione, E. Budinska, V. De Vriendt, MF. Baietti, M. Steklov, B. Jacobs, N. Hoe, S. Singh, NS. Imjeti, P. Zimmermann, A. Sablina, S. Tejpar,
520    9_
$a Inappropriate activation of epidermal growth factor receptor (EGFR) plays a causal role in many cancers including colon cancer. The activation of EGFR by phosphorylation is balanced by receptor kinase and protein tyrosine phosphatase activities. However, the mechanisms of negative EGFR regulation by tyrosine phosphatases remain largely unexplored. Our previous results indicate that protein tyrosine phosphatase receptor type O (PTPRO) is down-regulated in a subset of colorectal cancer (CRC) patients with a poor prognosis. Here we identified PTPRO as a phosphatase that negatively regulates SRC by directly dephosphorylating Y416 phosphorylation site. SRC activation triggered by PTPRO down-regulation induces phosphorylation of both EGFR at Y845 and the c-CBL ubiquitin ligase at Y731. Increased EGFR phosphorylation at Y845 promotes its receptor activity, whereas enhanced phosphorylation of c-CBL triggers its degradation promoting EGFR stability. Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO leads to high resistance of colon cancer to EGFR inhibitors. Our results not only highlight the PTPRO contribution in negative regulation of SRC/EGFR signaling but also suggest that tumors with low PTPRO expression may be therapeutically targetable by anti-SRC therapies.
650    _2
$a Caco-2 buňky $7 D018938
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a nádory tračníku $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D003110
650    _2
$a epidermální růstový faktor $x farmakologie $7 D004815
650    _2
$a HCT116 buňky $7 D045325
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a buňky HT-29 $7 D019073
650    _2
$a lidé $7 D006801
650    _2
$a MAP kinasový signální systém $7 D020935
650    _2
$a fosforylace $7 D010766
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a protoonkogenní proteiny c-cbl $x metabolismus $7 D050721
650    _2
$a chinazoliny $x farmakologie $7 D011799
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a erbB receptory $x antagonisté a inhibitory $x metabolismus $7 D066246
650    _2
$a tyrosinfosfatasy receptorového typu, třída 3 $x biosyntéza $x genetika $x metabolismus $7 D054631
650    _2
$a signální transdukce $7 D015398
650    _2
$a skupina kinas odvozených od src-genu $x metabolismus $7 D019061
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vazquez, Iria $u Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Vecchione, Loredana $u Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
700    1_
$a Budinska, Eva $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a De Vriendt, Veerle $u Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
700    1_
$a Baietti, Maria Francesca $u Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Steklov, Mikhail $u Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Jacobs, Bart $u Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
700    1_
$a Hoe, Nicholas $u Prometheus Laboratories, San Diego, CA, USA.
700    1_
$a Singh, Sharat $u Prometheus Laboratories, San Diego, CA, USA.
700    1_
$a Imjeti, Naga-Sailaja $u Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068-CNRS UMR7258, Aix-Marseille Université, Institut Paoli-Calmettes, Marseille, France. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Zimmermann, Pascale $u Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068-CNRS UMR7258, Aix-Marseille Université, Institut Paoli-Calmettes, Marseille, France. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Sablina, Anna $u Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium. Center for Human Genetics, KU Leuven, Leuven, Belgium.
700    1_
$a Tejpar, Sabine $u Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 5, č. 20 (2014), s. 10070-83
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25301722 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151014103921 $b ABA008
999    __
$a ok $b bmc $g 1092675 $s 914925
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 5 $c 20 $d 10070-83 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Možnosti archivace